Angiotensin Converting Enzyme 2 News and Research

RSS
SARS-CoV-2 variants of concern employ different strategies of antibody escape

SARS-CoV-2 variants of concern employ different strategies of antibody escape

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Activation of integrins by SARS-CoV-2 may be key to infection

Activation of integrins by SARS-CoV-2 may be key to infection

Variations in human ACE2 genetics associated with coronavirus susceptibility

Variations in human ACE2 genetics associated with coronavirus susceptibility

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

SARS-CoV-2 reprograms host chromatic network to induce immune dysfunction

SARS-CoV-2 reprograms host chromatic network to induce immune dysfunction

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

Scientist explore conserved RNA elements as potential targets for anti-SARS-CoV-2 drugs

Scientist explore conserved RNA elements as potential targets for anti-SARS-CoV-2 drugs

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Potent nasal vaccine protects non-human primates from SARS-CoV-2

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Next-generation COVID-19 vaccine provides robust immunity against SARS-CoV-2 in mice

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies